Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Assessment of disease activity in muscular dystrophies by noninvasive imaging
Katie K. Maguire, … , Sedona Speedy, Thomas A. Rando
Katie K. Maguire, … , Sedona Speedy, Thomas A. Rando
Published April 24, 2013
Citation Information: J Clin Invest. 2013;123(5):2298-2305. https://doi.org/10.1172/JCI68458.
View: Text | PDF
Technical Advance

Assessment of disease activity in muscular dystrophies by noninvasive imaging

  • Text
  • PDF
Abstract

Muscular dystrophies are a class of disorders that cause progressive muscle wasting. A major hurdle for discovering treatments for the muscular dystrophies is a lack of reliable assays to monitor disease progression in animal models. We have developed a novel mouse model to assess disease activity noninvasively in mice with muscular dystrophies. These mice express an inducible luciferase reporter gene in muscle stem cells. In dystrophic mice, muscle stem cells activate and proliferate in response to muscle degeneration, resulting in an increase in the level of luciferase expression, which can be monitored by noninvasive, bioluminescence imaging. We applied this noninvasive imaging to assess disease activity in a mouse model of the human disease limb girdle muscular dystrophy 2B (LGMD2B), caused by a mutation in the dysferlin gene. We monitored the natural history and disease progression in these dysferlin-deficient mice up to 18 months of age and were able to detect disease activity prior to the appearance of any overt disease manifestation by histopathological analyses. Disease activity was reflected by changes in luciferase activity over time, and disease burden was reflected by cumulative luciferase activity, which paralleled disease progression as determined by histopathological analysis. The ability to monitor disease activity noninvasively in mouse models of muscular dystrophy will be invaluable for the assessment of disease progression and the effectiveness of therapeutic interventions.

Authors

Katie K. Maguire, Leland Lim, Sedona Speedy, Thomas A. Rando

×

Figure 1

The expression of luciferase in resting and injured muscle in Pax7CreER/LuSEAP mice.

Options: View larger image (or click on image) Download as PowerPoint
The expression of luciferase in resting and injured muscle in Pax7CreER/...
(A) A luciferase-expressing cell (arrows) residing under the basal lamina (laminin staining) and expressing the satellite cell marker syndecan-4 1 week after tamoxifen administration to a Pax7CreER/LuSEAP mouse. Scale bar: 10 μm. (B) Three days after an acute injury to the right TA muscle of a Pax7CreER/LuSEAP mouse, luciferase signals were detectable only in the injured limb. Scale to the right of the image represents photon emission from the tissue surface and is expressed as p/s/cm2/sr (or radiance). (C) Luciferase-expressing cells contributed to regenerative myotubes and nascent myofibers during the regenerative process (days 3–10), but were absent in the uninjured muscle. Scale bar: 50 μm.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts